Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series

Lung Cancer

Volumn 108, Issue , 2017, Pages 22-28

  Tchekmedyian, Nishan ^a   Mudad, Raja ^b   Blanco, Fernando F ^c   Raymond, Victoria M ^c   Garst, Jordan ^d   Erlander, Mark G ^c   Haura, Eric ^a   Berz, David ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Trovagene Inc   (United States)

^d Beverly Hills Cancer Center   (United States)

Author keywords

Circulating tumor DNA; EGFR; Longitudinal monitoring; Non small cell lung cancer; Systemic mutation burden; Tyrosine kinase inhibitors

Indexed keywords

CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; OSIMERTINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADRENAL METASTASIS; ADULT; ARTICLE; ATELECTASIS; BLOOD; BRAIN DAMAGE; BRAIN EDEMA; BRAIN TOMOGRAPHY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DIZZINESS; DNA ISOLATION; DNA MUTATIONAL ANALYSIS; DRUG WITHDRAWAL; EXCISION; FEMALE; GENE MUTATION; HEADACHE; HUMAN; KIDNEY METASTASIS; LUNG NODULE; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MIDDLE AGED; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; URINALYSIS; URINE; WHOLE BRAIN RADIOTHERAPY; X-RAY COMPUTED TOMOGRAPHY; ALLELE; AMINO ACID SUBSTITUTION; BIOPSY; CASE REPORT; GENETICS; LONGITUDINAL STUDY; LUNG TUMOR; MORTALITY; MUTATION; PROCEDURES; TREATMENT OUTCOME;

ALLELES; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; DNA, NEOPLASM; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85014466305     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.02.010     Document Type: Article

References (20)

1. [1] Lynch, T.J., Bell, D.W., Sordella, R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:21 (2004), 2129–2139, 10.1056/NEJMoa040938.
2. [2] Paez, J.G., Jänne, P.A., Lee, J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:5676 (2004), 1497–1500, 10.1126/science.1099314.
3. [3] Pao, W., Miller, V., Zakowski, M., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101:36 (2004), 13306–13311, 10.1073/pnas.0405220101.
4. [4] Lilenbaum, R.A., Horn, L.A., Management of EGFR mutation-positive non-small cell lung cancer. J. Natl. Compr. Cancer Netw. 14:5 Suppl (2016), 672–674.
5. [5] Russo, A., Franchina, T., Ricciardi, G.R.R., et al. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives. Oncotarget 6:29 (2015), 26814–26825, 10.18632/oncotarget.4254.
6. [6] Jänne, P.A., Yang, J.C.-H., Kim, D.-W., et al. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N. Engl. J. Med. 372:18 (2015), 1689–1699, 10.1056/NEJMoa1411817.
7. [7] Arcila, M.E., Oxnard, G.R., Nafa, K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790 M mutation using a locked nucleic acid-Based assay. Clin. Cancer Res. 17:5 (2011), 1169–1180, 10.1158/1078-0432.CCR-10-2277.
8. [8] Douillard, J.-Y., Ostoros, G., Cobo, M., et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J. Thorac Oncol. Off. Publ. Int. Assoc. Stud. Lung Cancer 9:9 (2014), 1345–1353, 10.1097/JTO.0000000000000263.
9. [9] Meric-Bernstam, F., Brusco, L., Shaw, K., et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J. Clin. Oncol. 33:25 (2015), 2753–2762, 10.1200/JCO.2014.60.4165.
10. [10] Spicer, J., Tischer, B., Peters, M., EGFR mutation testing and oncologist treatment choice in advanced nsclc: global trends and differences. Ann. Oncol., 26(Suppl. 1), 2015, i60, 10.1093/annonc/mdv128.04.
11. [11] Hyman, D.M., Diamond, E.L., Vibat, C.R.T., et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 5:1 (2015), 64–71, 10.1158/2159-8290.CD-14-0742.
12. [12] Reckamp, K.L., Melnikova, V.O., Karlovich, C., et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J. Thorac Oncol. 11:October (10) (2016), 1690–1700, 10.1016/j.jtho.2016.05.035.
13. [13] Wakelee, H.A., Gadgeel, S.M., Goldman, J.W., et al. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J. Clin. Oncol., 34, 2016 (suppl; abstr 9001), http://meetinglibrary.asco.org/content/167439-176. Accessed 30 September 30 2016.
14. [14] Yanagita, M., Redig, A.J., Paweletz, C.P., et al. A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.(June), 2016, 10.1158/1078-0432.ccr-16-0909.
15. [15] Klempner, S.J., Gershenhorn, B., Tran, P., et al. BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy. Cancer Discov. 6:6 (2016), 594–600, 10.1158/2159-8290.CD-15-1192.
16. [16] Tie, J., Wang, Y., Tomasetti, C., et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med., 8(346), 2016, 346ra92, 10.1126/scitranslmed.aaf6219.
17. [17] Karlovich, C., Goldman, J.W., Sun, J.-M., et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin. Cancer Res. 22:10 (2016), 2386–2395, 10.1158/1078-0432.CCR-15-1260.
18. [18] Mok, T., Wu, Y.-L., Lee, J.S., et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 21:14 (2015), 3196–3203, 10.1158/1078-0432.CCR-14-2594.
19. [19] Oxnard, G.R., Paweletz, C.P., Kuang, Y., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20:6 (2014), 1698–1705, 10.1158/1078-0432.CCR-13-2482.
20. [20] Bettegowda, C., Sausen, M., Leary, R.J., et al. Detection of circulating tumor DNA in early- and late-Stage human malignancies. Sci. Transl. Med., 6(224), 2014, 10.1126/scitranslmed.3007094 (224ra24-224ra24).